Olaparib Improves Progression-Free Survival in Relapsed Ovarian Cancer
Olaparib as maintenance treatment significantly improved progression-free survival in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.
Olaparib as maintenance treatment significantly improved progression-free survival in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.
The cervical-cancer screening program used by the Netherlands is as effective as the screening protocol used in the United States, producing similar cervical cancer mortality rates in spite of less screening.
Accumulation of telomeric allelic imbalance predicts sensitivity to cisplatin.
In what is believed to be the first reported case of dermatomyositis-associated panniculitis in the setting of ovarian adenocarcinoma and a recurrent malignancy, a 63-year-old woman sustained clinical improvement following treatment with prednisone and oral methotrexate.
(ChemotherapyAdvisor) – New guidelines from the United States Preventive Services Task Force (USPSTF) recommend screening for cervical cancer in women 21-65 years of age with cytology (Papanicolaou smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, a combination of cytology with human papillomavirus (HPV) testing every 5 years.
An article published on March 7 in PLoS Medicine revealed that women who use injectable contraceptives increased their risk of developing certain female cancers.
A study of 25,871 women has found that the most effective approach for cervical screening is to conduct primary high-risk human papilloma virus (hrHPV) screening and, if positive for grade 3 or worse high-grade cervical intraepithelial neoplasia (CIN3+), repeat cytology.
The North American Menopause Society (NAMS) has published a 2012 position statement that provides updated evidence for use of hormone therapy for postmenopausal women.
Endometriosis increases risk for specific histologic subtypes of ovarian cancer.
Thrombocytosis is significantly associated with advanced disease and shorted survival in patients with epithelial ovarian cancer, a study published in February 16 issue of The New England Journal of Medicine reported.